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Abstract: Opioid use disorder is a well-established and growing problem in the United States.
It is responsible for both psychosocial and physical damage to the affected individuals with a
significant mortality rate. Given both the medical and non-medical consequences of this epidemic,
it is important to understand the current treatments and approaches to opioid use disorder and
acute opioid overdose. Naloxone is a competitive mu-opioid receptor antagonist that is used for
the reversal of opioid intoxication. When given intravenously, naloxone has an onset of action
of approximately 2 min with a duration of action of 60–90 min. Related to its empirical dosing
and short duration of action, frequent monitoring of the patient is required so that the effects of
opioid toxicity, namely respiratory depression, do not return to wreak havoc. Nalmefene is a pure
opioid antagonist structurally similar to naltrexone that can serve as an alternative antidote for
reversing respiratory depression associated with acute opioid overdose. Nalmefene is also known
as 6-methylene naltrexone. Its main features of interest are its prolonged duration of action that
surpasses most opioids and its ability to serve as an antidote for acute opioid overdose. This can be
pivotal in reducing healthcare costs, increasing patient satisfaction, and redistributing the time that
healthcare staff spend monitoring opioid overdose patients given naloxone.
Keywords: nalmefene; opioid overdose; naloxone; harm reduction; antidote
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1. Introduction
Reaching an equilibrium between the use of opioids for chronic pain, while balancing
abuse and overdose risk has been a pertinent, costly challenge in medicine for decades [1].
Before 1990, physicians were reprimanded for the meager treatment of pain, followed by
a shift toward aggressive opioid pain treatment in the late 1990s [2]. From 2011 to 2020,
prescriptions for opioids decreased by more than 60%; however, overdose deaths increased
by approximately two times during the same time frame [3,4]. Now, we are fighting a
recent rise in preventable overdose deaths that sparked in 2019 with the more frequent use
of fentanyl, which can be more potent, long-lasting, and cheaper than heroin [5,6]. Fentanyl
is easier to synthesize and is more potent than heroin, becoming a more commonly abused
drug in the U.S. [7].
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The CDC reported in July 2021 that overdose deaths in 2020 displayed the largest
increase in nearly 50 years, from 70,980 deaths in 2019 to 93,331 deaths in 2020 [8]. Additionally, deaths caused by opioid-derived substances rose from nearly 70% in 2019
to approximately 75% in 2020 [8]. The COVID-19 pandemic and its consequences are
suspected of having played a significant role in the rise.
The primary drug for combatting acute opioid overdose has been naloxone. In overdose situations and for clinical uses, the respiratory depression and sedative effects of
opioids can occur for several hours after administration [9,10]. This requires more hours of
patient monitoring for signs of respiratory depression and potential repeated administration of naloxone, as the duration of action (DOA) of naloxone is generally 64 min [11]. This
brings light to the pertinent issue associated with naloxone: its DOA is less than that of
most frequently abused opioids [12,13].
This central issue with naloxone has led much research toward an alternative opioid
antagonist with a longer DOA. Nalmefene is a pure opioid antagonist structurally similar
to naltrexone that can serve as an alternative antidote for reversing respiratory depression
associated with acute opioid overdose. The key feature of nalmefene is its increased DOA
being several hours longer than naloxone and its ability to serve as an antidote during
acute opioid overdose, unlike naltrexone. This can help patients be discharged earlier and
decrease nursing observation by 2–4 h [11,12]. An alternative opioid overdose antidote on
the market is further beneficial with the marked rise in opioid overdose deaths.
On 13 March 2019, the U.S. Food and Drug Administration (FDA) granted Fast Track
designation for Purdue Pharma L.P.’s Nalmefene HCl injections to treat known or suspected
opioid overdose [14]. Reasons for Fast Track designation include the marked rise in opioid
overdoses in the U.S. and the subsequent need for more reversal agents of similar or better
efficacy than naloxone.
Though nalmefene has displayed efficacy in treating alcohol dependence in humans [15], this review will focus on nalmefene’s implications with opioid use disorder
(OUD) and opioid overdose. This study was designed to analyze the efficacy and practicality of nalmefene treatment in OUD and suspected opioid overdose cases by reviewing the
history of nalmefene research in human subjects.
2. Opioid Use Disorder/Overdose
Opioid analgesics are widely regarded as a necessary and legitimate medical therapy
for people suffering from severe acute pain and chronic pain that is unresponsive to other
therapies. Therapeutic success is dependent on proper patient selection, administration,
and close monitoring throughout treatment [16]. However, opioid misuse and substance
use disorders have imposed a major health epidemic on the United States population.
From 1999 to 2017, more than 700,000 U.S. residents died from a drug overdose, and over
two-thirds were attributable to opioids [17]. In U.S. adults aged 24 to 35, 20% of all deaths
are attributable to opioids [18]. Given the burden of the opioid epidemic on our society, an
understanding of the problem we face may equip medical personnel with the knowledge
to cultivate a safer therapeutic environment for the future.
Opiates such as morphine and heroin, naturally derived from the opium poppy, were
first recognized in the 1800s and marketed to physicians and patients as a safe and effective
way to alleviate suffering [19]. Opiates were employed freely to treat everyday conditions,
including cough, diarrhea, mild pain, and anxiety. Increased use brought awareness to
the disadvantages by way of the 1915 Harrison Anti-Narcotic Act [20]. These initiatives
sought to decrease opiate consumption through regulation of opiate prescribing and dispensing practices. Attitudes towards opioid safety and prescribing practice changed in
the 1980s; an editorial in Advances in Alcohol and Substance Abuse wrote that physicians
markedly undertreat pain in addition to expressing concern for “opiophobia” as an undocumented and illegitimate fear that patients will become addicted to opioids when used
appropriately [21]. Popular thought shifted during this time, favoring heavy analgesia
coverage over the side effect profile of narcotics. In conjunction with unsubstantiated
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physician-targeted marketing schemes by pharmaceutical companies purporting superior
safety profiles in extended-release oxycodone, subscribing rose steadily until a peak in 2010
at 225 million prescriptions [22]. That was equal to over 81 prescriptions per 100 persons in
the U.S. Additionally, there was a rise in non-medical use or diversion in the U.S., wherein
between 1999 and 2009, death rates involving prescription opioids increased four-fold [23].
3. Current Treatment of Opioid Use Disorder/Overdose
Opioid use disorder is a well-established and growing problem in the United States
responsible for both psychosocial and physical damage to the affected individuals, in addition to a nearly 10-fold higher mortality rate relative to the general public [24]. Given both
the medical and non-medical consequences of this epidemic, it is important to understand
the current treatments and approaches to acute opioid overdose.
Naloxone is a competitive mu-opioid receptor antagonist used to reverse opioid intoxication [25]. When given intravenously, naloxone has an onset of action of approximately
2 min with a duration of action of 60–90 min [25]. Related to its empirical dosing and
short duration of action, frequent monitoring of the patient is required so that the effects of
opioid toxicity, namely respiratory depression, do not return to wreak havoc [25]. Naloxone
has few adverse effects which are commonly linked to withdrawal from opioids, such as
anxiety, aggression, nausea, vomiting, diarrhea, abdominal pain, and rhinorrhea [26].
Despite the advantages of naloxone in treating acute opioid overdose, emergency
departments prescribe and dispense naloxone relatively infrequently [27]. A group of
surveyed emergency departments in New England demonstrated that only 12% would
prescribe naloxone at discharge for patients at high risk of overdose. A similar survey of
200 emergency department physicians demonstrated a broad acceptance and willingness
to improve opioid harm-reduction strategies. Still, it also revealed that of the surveyed
physicians, only 1.7% had personally prescribed naloxone, and only 10.3% had referred
at-risk patients to naloxone distribution programs [27].
Another basic pillar in addressing the risks of opioid overdose and fatality is public
access to naloxone and overdose education programs (OEPs). Reviews conducted by both
the World Health Organization and the Canadian Agency for Drugs and Technologies in
Health established that OEPs have demonstrated success in reducing fatality from overdose [28,29]. Mitchell et al. describe the success public policy has had as well, citing the
successes of government-funded naloxone distribution programs in Scotland, England, and
Canada, and in California, Massachusetts, New York, Rhode Island, and North Carolina in
the United States [28]. One program based in San Francisco found that approximately 21%
of program participants had used naloxone to reverse an opioid overdose, with a documented 89% success rate [28]. These educational programs should be directed at healthcare
providers, as well. Through an educational program run by the United States Veterans
Health Administration, naloxone prescription rates tripled in 12 months and septupled by
24 months [27]. Policies aimed at reducing liability for naloxone prescriptions, increasing
public access to and education of naloxone use, and encouraging/mandating co-prescribing
of naloxone with opioids have all been shown to reduce overdose fatalities [25,27–29].
A discussion of OUD treatment would be remiss if it did not include a discussion of
naltrexone. Naltrexone is a µ-opioid receptor (MOR) and is used for both the treatment of
alcohol use disorder and OUD. It also blocks delta and kappa receptors, as well. Naltrexone
blocks the euphoric effects of opioids and is used to reduce and suppress cravings [30].
Naltrexone cannot, however, reverse an overdose or treat opioid withdrawal. It is used
alone or can be combined in a formulation with buprenorphine to reduce the potential
for abuse. Nalmefene is structurally similar to naltrexone, but it has a longer half-life and
better bioavailability.
4. Nalmefene
Nalmefene HCl is a pure opioid receptor antagonist and is considered the longestacting parenteral opioid antagonist commercially available for OUD and opioid overdose.
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It is a white crystalline substance, and its chemical name is 17-(cyclopropylmethyl)-4,5epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt. It can be used to prevent or
counter the various consequences of opioid overdose or post-surgery opioid effects, such
as respiratory depression and sedation. Desirable outcomes of nalmefene administration
include alleviation of respiratory depression, nerve center depression, and hypotension
associated with prolonged opioid receptor activation [31]. A pill form of nalmefene is
manufactured in Japan, England, and other European countries under the brand name of
Selincro® for the treatment of alcohol dependence in decreasing alcohol intake [32].
In 1995, nalmefene HCl was granted approval by the U.S. FDA to treat known or
suspected opioid overdose and was sold under the brand name Revex® . Nalmefene can be
administered intravenously (IV), intramuscularly (IM), or subcutaneously (SC). Nalmefene
is currently sold in two doses, with the concentration being dependent on postoperative
or overdose use. Nalmefene is available in a blue-labeled ampul containing 1 mL at a
concentration of 100 µg/mL for postoperative use. For opioid overdose reversal, nalmefene
is available in a green-labeled ampul containing 2 mL at a 1 mg/mL concentration, being
ten times more concentrated than the postoperative formulation [33]. An initial dose of
0.5 mg/70 kg for opioid overdose reversal is recommended and can be followed up 2–5 min
with a 1.0 mg/70 kg dose [33]. Intravenously administration of nalmefene generally takes
2 min for initiation of opioid reversal [33]. If nalmefene is administered via intramuscular
(IM) or subcutaneous (SC) routes, it may take 5–15 min for a 1 mg dose to be effective [31].
Nalmefene is well tolerated in human subjects for up to 24 mg of IV doses [34]. In
most studies, its side effects were transient, relatively mild, and similar to naloxone’s side
effects. The main side effects for both are nausea, vomiting, tachycardia, hypertension,
pain, fever, and dizziness [31]. However, it can produce acute withdrawal symptoms in
those physically dependent on opioids [31]. Furthermore, nalmefene is only known to have
net antagonistic effects on opioid receptors and is not considered abuse potential nor cause
physical dependence [29].
Special caution should be considered with administering nalmefene to pregnant or
nursing mothers, neonates, pediatric patients, and patients over 65 years of age. There
has not been sufficient research in these populations to deem it safe for use. Regarding
reproduction, it is worthy to note that nalmefene did not affect fertility in rats, and its
partial kappa-opioid receptor activity was found to increase serum prolactin levels and
luteinizing hormone pulsatility in humans [35,36].
4.1. Mechanism of Action
Nalmefene is structurally similar to naltrexone and also known as 6-methylene naltrexone [37]. The 6-methylene group in nalmefene replaces the 6-ketone group of naltrexone. Its methylene group is suspected to result in increased DOA, higher affinity at
MOR, a G-protein coupled receptor [38]. It has a greater oral bioavailability relative to
naloxone [39–42]. It acts as an opioid receptor modulator on µ-, κ-, and δ-opioid receptors.
K-opioid receptors (KORs) aid in mediating sedation and partially respiratory depression [9]. MORs play an important role in euphoria, physical dependence, and the
respiratory depression associated with opioid overdose [9,43]. δ-opioid receptors (DORs)
are implicated with positive affect and decreased anxiety [43].
Nalmefene is known to be a competitive antagonist at the µ- and δ-opioid receptors [44]. It has the strongest affinity and antagonistic effects at MOR, responsible for the
decreased response to CO2 and subsequent respiratory depression associated with opioid
overdose [45]. These antagonistic effects are critical for its use as a reversal agent upon
injection to halt the potentially fatal effects of respiratory depression and sedation caused
by acute opioid overdose.
Nalmefene possesses partial agonistic affinity at κ-opioid receptors (KOR), and partial
agonism of KOR leads to a net antagonistic effect. Studies suggest that its action at KOR
decreases dopamine in the nucleus accumbens and subsequent inhibition of the positive
reinforcement associated with the mesolimbic reward pathway [37]. Because ethanol leads
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to a rise in endogenous opioids such as β-endorphin, a MOR agonist, and dynorphin, a
KOR agonist, orally administered nalmefene effectively combats their effects and decreases
alcohol consumption in combination with psychosocial support [31].
Nalmefene possesses MOR and KOR binding affinities comparable to naloxone [36].
Nalmefene has the greatest affinity for KOR, followed closely by MOR, and significantly
less affinity for DOR [36]. Its affinity for DORs is 200-fold less than its affinity for KOR and
can be considered to play a smaller role in its physiological effects [36].
Nalmefene also has a higher potency for opioid receptors than naloxone. Its potency
is 4 times higher than naloxone at MOR and slightly more potent at KOR [46]. Nalmefene
also has a longer elimination half-life, ranging from 8 to 11 h, and a longer duration of
action of 1–4 h [46]. The longer duration of action is also associated with the medication’s
slow dissociation from the opioid receptor [46].
4.2. Pharmacokinetics/Pharmacodynamics
Pharmacodynamic studies have found a clinically competent reversal of opioid effects,
including respiratory depression, sedation, and hypotension. Nalmefene has a longer DOA
than naloxone at fully reversing doses with zero agonist activity [31]. The same studies
have not reproduced any respiratory depression, sedation, hypotension, psychotomimetic
effects, or pupillary constriction. There was no pharmacological activity observed when
nalmefene was administered in the absence of opioid agonists. Nalmefene has not been
shown to produce physical dependence, tolerance, or abuse potential, although it can
produce acute withdrawal symptoms in opioid-dependent individuals.
The pharmacokinetic profile of nalmefene is complex and has been intensely studied.
It is absorbed with complete bioavailability following IM and subcutaneous administration
relative to IV in 12 subjects [31]. As a result, nalmefene will routinely be given as an IV
bolus, but in failed venous access, it can also be given SC or IM with superior efficacy.
Time to maximum plasma concentration is 2.3 h ± 1.1 h following IM administration
compared to 1.5 h ± 1.2 h following SC administration and 5–15 min after 1 mg IV bolus in
emergencies. Nalmefene is distributed rapidly following a 1 mg parenteral dose, blocking
over 80% of brain opioid receptors within 5 min. The steady-state concentration is reached
at 8.6 ± 1.7 L/kg. Ultrafiltration studies demonstrated that 45% of nalmefene is bound
to plasma proteins and distributed in a 2:1 ratio of RBC:plasma [31]. Population kinetic
models have shown that nalmefene distribution is age-dependent, with elderly populations
having a faster distribution half-life, a smaller volume of distributions (Vd ), and higher
initial concentrations than younger populations [47]. The liver primarily metabolizes
nalmefene in a glucuronide conjugation reaction with subsequent excretion in urine [48].
The N-dealkylated metabolite has minimal pharmacologic activity. Nalmefene is eliminated
biexponentially with a systematic clearance of 0.8 ± 0.2 liters/hour/kilogram and renal
clearance of 0.08 ± liters/hour/kilogram [48]. In summary, a robust population PK model
found that a single 20 milligram dose of nalmefene produced a 24 h therapeutic effect in
95% of the population [49].
5. Nalmefene vs. Naloxone
Nalmefene and naltrexone are pure opioid antagonists that block receptor activity of
the mu, kappa, and delta sub receptors in the CNS [50]. Nalmefene is a methylene analog
of naltrexone that was originally approved in 1995 as a more potent analog. Nalmefene
is has a slightly slower onset of action when given IV (5–15 min compared to 1–2 min
with naloxone), equipotent binding power compared to naloxone, a longer DOA, and
a much longer plasma half-life (8–11 h compared to 80 min with naloxone) [51]. Both
naloxone and nalmefene are indicated in acute opioid intoxication characterized by respiratory depression, coma, or hypotension. Off-label uses for both agents include clonidine,
benzodiazepine, ethanol, or valproic acid overdoses [52]. Overall, both agents are useful
for acute opioid withdrawal despite a longer DOA, similar potency, and a longer onset of
action is seen in nalmefene compared to naloxone.
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6. Naltrexone
Naltrexone is a pure opioid antagonist and is used for the reduction of cravings and
consumption of both opioids and alcohol. Of note, naltrexone is not indicated for acute
opioid intoxication. In fact, naltrexone has been implicated in acute opioid overdose deaths
as it can lower the patient’s tolerance to opioids. These overdoses happen after a period of
abstinence and discontinuation of naltrexone [30]. This makes them more susceptible to
overdose with a smaller amount of opioids used than in the past.
Naltrexone comes in an oral or a long-acting injectable form, called vivitrol. Historically, patients would have to show that oral naltrexone was tolerable without an increase
in liver function enzymes prior to starting the injectable form. It is because of this that
naltrexone has not been useful in an acute overdose situations since oral medicine cannot
be given to someone who is unconscious. The injectable form comes with another set of
barriers. Each injection is costly, at around USD 1400 a shot. It is because of this that not
all pharmacies can afford to carry it, let alone have it accessible for emergency medical
services. Table 1 shows a comparison of naloxone, nalmefene, and naltrexone.
Table 1. The comparison of naloxone, nalmefene, and naltrexone.
Medication

Mechanism
of Action

Pharmacokinetics/Dynamics

Uses

Routes of
Administration

Naloxone

Antagonist
of MOR

Half-life: 30–120 min
Duration of Action: 1–4 h
Metabolized by: Liver

Reversal of
Opioid Overdose

Intranasal
Subcutaneous
Endotracheal
Sublingual
Intralungual
Submental
Intravenous
Intramuscular

Nalmefene

Antagonists at
MOR and
DOR
Partial agoist
at KOR

Half-life: 8–11 h
Duration of action: 1–4 h
Metabolized by: Liver

Reversal of
Opioid Overdose

Intravenous
Intramuscular
Subcutaneously

Naltrexone

Pure
antagonist at
the MOR,
DOR,
and KOR

Half life: 4 h for naltrexone
and 13 h for active metabolite
of 6 beta-naltrexol
Duration of action:
Metabolized by: Liver

Can reduce and
suppress opioid
and alcohol
cravings
Not used in
opioid overdose

Oral
Intramuscular

7. Clinical Studies: Safety and Efficacy
A broad array of studies has investigated both the clinical efficacy and safety of
nalmefene, especially as an acute treatment for opioid toxicity. In a review of the literature,
the following articles were chosen to best summarize and relay the relevant findings.
7.1. Kaplan Study
Kaplan et al. analyzed the differences between nalmefene and naloxone pharmacotherapy to treat suspected narcotic overdose in emergency department settings, specifically
evaluating differences in efficacy, safety, and symptoms of opioid withdrawal [11]. This
study compiled data from adult patient populations (≥18 years old) across nine primarily
urban teaching hospitals in the United States, randomizing those patients selected into
one of three treatment arms: up to four doses of either 1 milligram nalmefene, 2 milligram
nalmefene, or 2 milligram naloxone over the four-hour-long study [11]. All of this was conducted double-blindly, with the treatment arms randomized and the study drugs prepared
by and labeled indistinguishably by an outside facility [11]. Endpoints were measured using respiratory rate, Neurobehavioral Assessment Scale (NAS) scores, Opioid Withdrawal
Scale (OWS) scores, and the recorded incidents of adverse events following treatment [11].
A respiratory rate of 4 breaths/minute was assumed [11]. In addition to evaluating the
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drug’s effects on the patients, corresponding labs were drawn to quantify the concentration
of nalmefene in the patients’ plasma, with samples being drawn at 2- and 4-h intervals [11].
A total of 171 unique patients were evaluated on 176 emergency department (ED)
visits. Approximately half of the patients in each of the three treatment arms tested positive
for opioids during their visits [11]. Posing a complication to this study’s evaluation was that
>90% of the opioid-positive patients included also tested for additional illicit substances [11].
In each of the three treatment arms, changes to respiratory rates and the NAS scores were
similar, with both improving over time with the assigned treatments [11]. However, when
the data were stratified based on the patients’ screening positive for opioid toxicity during
their ED visit, more dramatic improvements to those measures were noted [11]. In looking
at the nalmefene groups, an improvement in the NAS scores was noted over the trended
interval from 20 min post-administration to 240 min, whereas those of the naloxone groups
demonstrated a decrease, and these differences were not statistically significant [11].
In evaluating the safety of the varying treatment arms, Kaplan et al. analyzed the
1 milligram nalmefene group against the naloxone group, chosen since naloxone is the
current standard of care for these patient visits [11]. Of those reporting adverse events
rated from mild to severe, over 30% of patients in the 2 milligram nalmefene treatment arm
experienced negative side effects, the most common of which were vomiting, nausea, and
tachycardia [11]. However, there were no clinically or statistically significant differences
between the 1 milligram nalmefene and the naloxone groups as evaluated by the efficacy
measures described in detail above, nor were there any significant differences between
the opioid-positive and negative groups [11]. Additionally, recorded vitals from both
opioid-positive and opioid-negative patient groups did not differ significantly from one
another, and all of the reported negative outcomes and side effects were determined by the
researchers not to have been related to either of the doses of nalmefene [11].
While there was no statistical or clinical difference noted among the three treatment
arms, Kaplan et al. acknowledge several limitations in their analysis. Related to the
high rate of multiple substances intoxicating, especially the opioid-positive patients, the
researchers note that a lack of recorded response to the study drugs does not preclude
opioid receptor antagonism, as the observed clinical signs attributed to opioid intoxication
could very well be related to other non-opioid substances [11]. Additionally, multiple
patients recorded as having responded to the study drugs were not confirmed to be opioidpositive by lab analysis, thus allowing for real potential differences in treatment arms that
were not detected by the study [11]. Conversely, suppose those who were falsely stratified
as opioid-negative were not equally distributed. In that case, bias could be introduced into
the results with the potential to mask a true difference among the treatment arms [11]. The
authors also raised questions regarding their study’s external validity, as all participants in
this study were treated in strictly urban teaching hospitals [11].
7.2. NIH Study
A different study conducted by Krieter et al. at the National Institute of Health (NIH)
sought to compare intranasal and intramuscular nalmefene as the acute treatment for opioid
overdose [53]. Data were collected from male and female inpatient participants aged 18 to
55 years old, with groups randomly assigned to one of six four-series treatment sequences
in a double-blind manner [53]. Each of the treatment doses were as follows: 3 milligram
intranasal nalmefene; 3 milligram 0.25% intranasal nalmefene-dodecyl maltoside (DDM);
1.5 milligram intranasal nalmefene; and 1.5 milligram intramuscular nalmefene. To form
the six different treatment sequences, each participant was randomized to one of the
intranasal nalmefene groups while each subject received the intramuscular nalmefene as
their final study dosage [53]. These intranasal nalmefene dosages were selected due to the
documented bioavailability of intranasal naloxone, a drug bearing significant structural
similarity to nalmefene [53]. Data were collected on subjects via ECG and venous blood
samples for plasma drug concentration, each collected at varying intervals from baseline to
72 h post-administration of their treatment drug [53]. Additionally, researchers monitored
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for adverse events by grading subjects’ experienced intranasal irritation and repeated
testing for the subjects’ retained sense of smell following the repeated administration of
intranasal medications [53].
Ten subjects fully completed the study requirements, including all the follow-up
parameters [53]. In the 3 milligram nalmefene group, labs could detect plasma drug
concentrations by the sample collected at 15 min post-administration [53]. However, in
analyzing plasma drug concentrations of patients treated with the adjuvant of 0.25% DDM,
the nalmefene levels were quantifiable by as little as 5 min [53]. In further analyzing the
drug concentrations trended out over 72 h, the addition of DDM to nalmefene reduced the
estimated time to maximum blood concentration from approximately 2 h to 15 min, while
also increasing the maximum plasma concentration by nearly double that of nalmefene
alone [53]. The addition of DDM to the intranasal nalmefene solution did not, however,
appear to alter the drug’s rate of elimination relative to nalmefene alone [53]. Ten of the
fourteen original study subjects experienced some degree of adverse effects of the study
drugs, most of which were vomiting, nausea, and dizziness [53]. All of these reported
negative outcomes were mild in severity, and there was no loss or alteration to the sense of
smell noted by any of the study subjects [53].
Despite the improvements noted in overall pharmacodynamics and following a review
of relevant research, Krieter et al. do not suggest that these improvements, however
nominally impressive, actually result in any changes in patient outcomes [53]. An obvious
issue with this study includes limitations in overall generalizability due to the small sample
size involved; as such, broad-reaching inferences and conclusions regarding the observed
pharmacodynamics are highly limited [53].
7.3. Tufts University Study
A study conducted by Connelly et al. at the Tufts University School of Medicine
attempted to evaluate nalmefene versus naloxone as prophylaxis against adverse effects of
intrathecal opioids in the specific patient subset of those undergoing cesarean delivery [54].
The stated goal was to discover which treatment arms demonstrated the greatest reduction
in opioid-induced side effects while not compromising the initial intrathecal anesthetic [54].
At the start of the study, 80 patients were randomly assigned in a double-blind manner
to one of four treatment arms: saline, 0.25 microgram/kilogram intravenous nalmefene
every 12 h for two doses, 0.50 microgram/kilogram intravenous nalmefene every 12 h for
two doses, and a 48 mcg/h naloxone infusion [54]. The intrathecal agents administered to
the subjects involved in the study were 50–70 milligrams of lidocaine with epinephrine
(200 micrograms), 10 micrograms of fentanyl, and 0.2 milligrams of morphine [54]. Endpoints were evaluated via Visual Analog Scores (VAS) to collect data at varying intervals
on the patients’ pain, sedation, and overall satisfaction with their spinal block [54].
The investigators found no statistical or clinical differences among the treatment arms
over the first day of observation, with no noted differences in recorded pain levels or patient
satisfaction [54]. Additionally, no difference among the varying groups was noted about
pruritis or nausea; however, a statistically significant increase in the rate of occurrence of
instances of vomiting was higher in both of the nalmefene treatment arms than that of the
control saline group [54].
Limitations to this study include the base assumption that the side effects being
monitored (pruritis, nausea, and vomiting) were strictly related to the opioid receptor
antagonism attained by the patients’ spinal blocks, as they are far more likely to be multifactorial [54]. Anecdotal evidence from the authors’ own clinical experience has shown that
the adverse effects of opioid spinal blocks are largely unrelieved by a reduction in the intrathecal dosing of those opioid agents [54]. Additionally, looking at the other literature on
the topic, multiple studies have demonstrated naloxone’s inability to reduce the negative
side effects of the spinal blocks without lowering the therapy’s analgesic capabilities [54].
Overall, related to the lack of evidence that treating these adverse effects prophylactically
makes any difference in patient outcomes, and due to the increased risks of vomiting in
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both of the nalmefene groups relative to the naloxone group, Connelly et al. recommend
that physicians treat these side effects as they arise [54].
7.4. Nalmefene: Treating Opioid-Induced Respiratory Depression
Konieczko et al. conducted a study specifically to analyze nalmefene’s ability to resolve
respiratory depression induced by morphine, especially relative to that accomplished by
the relatively short-lived naloxone with its half-life of 1–2.5 h [42]. The researchers used the
values of end-tidal PCO2 , rate of ventilation, and the subject’s response to hypercapnia [42].
These values were measured relative to the daily baseline collected from the study subjects
on each of the four days of the study [42].
Whereas the ventilatory rate demonstrated no significant changes across the treatment
arms, the subjects receiving nalmefene exhibited both immediate and sustained recovery
from morphine over the entire 6-h observation window [42]. This result for nalmefene
therapy is in stark contrast to the naloxone group, which charted an initial improvement in
ventilation and end-tidal CO2 before gradually returning to respiratory depression starting
at approximately 2.5 h post-administration [42]. These results suggest that respiratory rate
alone is an insufficient measure of the extent of respiratory depression while supporting
the advantages to nalmefene for safe treatment of opioid toxicity over a prolonged period
without the risk of the degree of short interval repeat drug administration required with
naloxone [42]. This is consistent with similar research conducted by Gal et al., which is
described more below.
7.5. Gal and DiFazio Study
A study conducted by researchers at the University of Virginia sought to quantify
both the opioid antagonist activity and duration of nalmefene by pretreating subjects
with varying doses of the study drug before submitting each to a 2 microgram/kilogram
fentanyl challenge [55]. Values measured included quantifiable signs of respiratory depression and the patients’ subjective responses to pain via a modified submaximal tourniquet
ischemia test [55]. The study subjects were randomized in a double-blind fashion into one
of four treatment sequences with the following: saline placebo, 0.5 milligram nalmefene,
1 milligram nalmefene, and 2 milligram nalmefene [55]. The 2-microgram fentanyl challenges were administered at 1, 2, 4, 6, and 8 h post-administration, with the respiratory
data gathered in a nearly continuous manner throughout each trial [55].
Nalmefene pretreatment resulted in consistently blunted fentanyl-induced respiratory
depression, with the high-dose nalmefene arm demonstrating no change in minute ventilation concerning baseline [55]. Additionally, the analgesic effects of the varying nalmefene
doses were directly parallel to the duration of resolution of the respiratory symptoms: the
2 milligram nalmefene dose resolved respiratory depression and blocked the analgesic
effects of the fentanyl challenges for the duration of the 8-h experiment; the 1 milligram
nalmefene dose resolved and blocked through the 6-h mark; and the 0.5 mg nalmefene dose
resolved and blocked through 4 h [55]. In terms of safety, no serious adverse events were
reported, though one subject in the high-dose nalmefene group complained of a temporary
(10 h) “gagging sensation” [55]. Table 2 outlines the studies discussed in this section.
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Table 2. Clinical safety and efficacy.
Study Name

Groups Studied and Intervention

Results and Findings

Conclusions

Kaplan et al.

171 unique adult patients with
signs of opioid overdose who
presented to the emergency
departments of multiple urban
teaching hospitals were studied to
determine the differences between
nalmefene and naloxone as acute
pharmacotherapies for opioid
overdose reversal. Subjects were
randomized into 1 mg nalmefene,
2 mg nalmefene, or 2 mg naloxone
treatment arms.

No clinically or statistically
significant differences in outcome
were appreciated between the
low-dose nalmefene and naloxone
groups. However, while the
high-dose nalmefene group
recorded similar symptomatic
improvement, over 30% of
patients in that group experienced
adverse side effects.

While there was no significant
difference in terms of
symptom resolution noted,
the generalizability of these
results is limited, and multiple
sources of statistical bias exist.

Krieter et al.

10 adult subjects completed the
entire course of this double-blind
experiment which sought to
compare outcomes between
intranasal (IN) and intramuscular
(IM) nalmefene for treatment of
acute opioid toxicity. Subjects were
divided into groups and treated
with varying sequences of 3 mg IN
nalmefene, 3 mg 0.25% IN
nalmefene-dodecyl maltoside
(DDM), 1.5 mg IN nalmefene, and
1.5 mg IM nalmefene.

In terms of absorption, the 3 mg
0.25% IN nalmefene-DDM
demonstrated the quickest time
both to maximum plasma
concentration and to point of
detectability in the plasma. The
addition of DDM also did not
appear to alter the rate of
elimination of nalmefene.

However impressive the
pharmacodynamic
improvements, there is no
evidence to support that these
changes actually resulted in
improved patient outcomes.

Connelly et al.

80 female patients scheduled to
undergo elective caesarean
deliveries were examined to
determine the effects of nalmefene
versus naloxone for the
prophylactic treatment of
opioid-induced adverse effects
secondary to intrathecal spinal
blocks (lidocaine w/ epinephrine,
fentanyl, and morphine). Treatment
regimens consisted of either saline,
0.25 mcg/kg IV nalmefene q12 h for
2 doses, 0.50 mcg/kg IV nalmefene
q12 h for 2 doses, or 48 mcg/h
naloxone infusion.

No statistical or clinical
differences were noted among the
treatment arms either in reported
pain levels, patient satisfaction, or
the adverse effects of pruritis and
nausea. However, both nalmefene
groups experienced a statistically
significant increase in episodes of
vomiting relative to other
treatment arms.

Related to the lack of evidence
that prophylactic intervention
changes patient outcomes and
due to the increased risks of
vomiting, the authors
recommend that physicians
treat side effects of intrathecal
spinal blocks as they arise.

Konieczko et al.

6 male subjects were studied to
analyze the nalmefene’s degree of
opioid antagonism and its half-life.
Treatment regimens included
universal treatment with
10 mg/70 kg IV morphine followed
by either IV saline, 0.4 mg/70 kg IV
nalmefene, 1.6 mg/70 kg IV
nalmefene, or 0.4 mg/70 kg
IV naloxone.

While the ventilatory rates
showed no significant differences
among treatment groups, those
receiving nalmefene showed both
immediate and sustained
recovery over the entire 6 h
observation period. The naloxone
group showed a similar initial
resolution of respiratory
depression, but that resolution
began to wane by approximately
2.5 h post-administration.

This study supports the
advantages of nalmefene
relative to naloxone for the
safe treatment of
opioid-induced respiratory
depression over a prolonged
period. Additionally, it
suggests that respiratory rate
alone is not an appropriate
measure for the degree of
respiratory depression.
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Table 2. Cont.
Study Name

Groups Studied and Intervention

Results and Findings

Conclusions

Gal and DiFazio

6 male subjects were analyzed to
determine opioid antagonist
activity and duration of action of
nalmefene. Subjects were
randomized into one of
four sequences consisting of
pretreatments with either IV saline,
0.5 mg IV nalmefene, 1 mg IV
nalmefene, or 2 mg IV nalmefene.
They were then subjected to 2 mcg
fentanyl challenges at
regular intervals.

High-dose nalmefene resulted in
no changes from baseline minute
ventilation and completely
blocked fentanyl’s analgesic
effects for the entire 8 h
observational period. Mid-dose
nalmefene prevented respiratory
depression and analgesia for 6 h,
while low-dose nalmefene
achieved the same for 4 h. No
serious adverse effects
were reported.

IV nalmefene’s duration of
action in blocking both the
respiratory and the analgesic
effects of fentanyl was directly
dose dependent. No
indication of agonist activity
was suggested by the
study outcomes.

8. Conclusions
The research nalmefene suggests that it can be a promising alternative for both acute
opioid overdose and continued treatment of OUD. Its main features of interest are its
prolonged DOA that surpasses that of most opioids and its ability to serve as an antidote
for acute opioid overdose. It is a versatile drug in the sense that it has various routes
of administration for different purposes. IV, IM, and SC can be used for respiratory
depression reversal and recovery from opioid-induced sedation. Nalmefene has a greater
oral bioavailability than naloxone.
However, research is limited in terms of positive research and more research should
be carried out to prove the superiority over the standard of care for opioid overdose, which
is naloxone.
The evolving literature is the reason why this review was created. If one was to
conduct a PubMed search for “nalmefene” and “opioid overdose”, there are only 11 articles
to be found. These articles include reviews and only a few studies that look at different
routes of nalmefene administration in the setting of opioid overdose. The difference
between naloxone and nalmefene with opioids with different durations of action has not
been performed, so a direct comment on which is different in clinical practice cannot be
made. However, naloxone can be limited by its duration of action since many opioids may
have a longer duration of action than naloxone itself. Since this could be the case, there is a
potential for opioid-mediated respiratory/central nervous system depression beyond the
duration of action of naloxone. This could render the potential reversal agent ineffective
or inviable. This is where nalmefene could potentially come into play; however, more
research should be carried out. Overdose antidotes may be pointless or viable depending
on the specific opioid agent and the best practice guidelines need to be developed to help
guide clinicians in managing these patients. It is important as well to consider different
doses of the opioid make it challenging to define best practice guidelines. To date, there are
limited data in the literature examining specific drugs and doses.
The foundational studies of nalmefene had small sample sizes in cohorts of men;
however, there is growing research regarding its implications with women and others
in the general population. When current study results are considered all together, they
show similar trends. For example, evidence from multiple studies displayed nalmefene’s
prolonged dose-dependent DOA, minimal effect on vital signs, and ability to reverse respiratory depression in cases of suspected opioid overdose. The methodology for determining
nalmefene’s effects on a cellular level, such as with direct positron emissions and analysis
of opioid receptors, was essential in piecing together its mechanism of action and pharmacokinetics. Current evidence has proved to be sufficient in most human subjects as the U.S.
The FDA approved its use, and future research will allow for even better generalization of
the data.
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Ensuring the safety of patients and reliable drug efficacy in urgent situations, such
as opioid overdose, are priorities in drug development. The repeated studies with nalmefene have provided evidence that it is well-tolerated in humans even at 12–24 times its
therapeutic doses. Its parenteral routes have been shown to provide consistent reversal of opioid-induced respiratory depression in various clinical settings and in cases of
opioid overdose.
Additionally, its desired characteristic of having a DOA longer than most opioids has
proven to be consistent for a variety of opioid substances, such as fentanyl, morphine, and
meperidine. This can be pivotal in reducing healthcare costs, increasing patient satisfaction,
and redistributing the time that healthcare staff spend monitoring opioid overdose patients
given naloxone. For these vast and unwavering reasons, nalmefene could be a key factor
for saving many lives in the current national opioid epidemic.
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